Eris Biotech

Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.

shared product terms: develop, cancer, immune, drug; shared affiliation: Y Combinator

Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunit

shared product terms: develop, cancer, therapeutic, immune; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity thro

shared product terms: develop, cancer, immune, system; shared product theme: health and clinical care; shared affiliation: Y Combinator

Our lead candidate is a multifaceted attack antibody for ovarian cancer. Our approach enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.

shared product terms: cancer, therapeutic, immune, system; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examp

shared product terms: develop, small, molecule, therapeutic; shared product theme: health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.

shared product terms: develop, therapeutic, drug, solid; shared product theme: health and clinical care; shared affiliation: Y Combinator